Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 07, 2017 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, July 07, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science Conference
June 14, 2017 07:30 ET
|
Paratek Pharmaceuticals
BOSTON, June 14, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that Evan Loh, MD, President, Chief Operating Officer and Chief Medical Officer, will...
New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections
June 03, 2017 13:15 ET
|
Paratek Pharmaceuticals
NEW ORLEANS, June 03, 2017 (GLOBE NEWSWIRE) -- New data presented today at ASM Microbe 2017 showed that Paratek Pharmaceuticals, Inc.’s (Nasdaq:PRTK) Phase 3 antibiotic omadacycline is highly active...
Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017
May 24, 2017 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, May 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented at ASM...
Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July
May 08, 2017 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, May 08, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update
May 04, 2017 07:00 ET
|
Paratek Pharmaceuticals
Reported positive Phase 3 study results with omadacycline in community-acquired bacterial pneumonia (CABP)Updated timing to submit regulatory application with U.S. FDA to as early as first quarter...
Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide Update on Clinical Progress on May 4, 2017
April 26, 2017 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, April 26, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic (PK/PD) Data
April 25, 2017 07:30 ET
|
Paratek Pharmaceuticals
VIENNA, Austria, April 25, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today presented new data from a Phase 1 study confirming that its once-daily oral and IV, broad...
New Health Economics Studies Highlight the Potential for Paratek Pharmaceuticals’ Omadacycline to Provide Cost-Savings Compared to Standard of Care for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections
April 24, 2017 07:00 ET
|
Paratek Pharmaceuticals
VIENNA, Austria, April 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that two cost benefit analyses presented at the annual meeting of the European...
Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China
April 24, 2017 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, April 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...